Document is current
Any future updates will be listed below
-
Authors
Nakajima, Waki
Arisawa, Tetsu https://orcid.org/0000-0001-7694-8728
Jitsuki, Susumu
Yamanoue, Tomomi
Fujikawa, Kaoru
Hara, Megumi
Sano, Akane
Takada, Yuuki
Iai, Ryunosuke
Kimura, Kimito
Suzuki, Masataka
Hatano, Mai
Syed, Shariful A. https://orcid.org/0000-0002-8636-8089
Yajima, Ayano
Nagata, Minami
Yatomi, Taisuke
Abe, Hiroki
Takahashi, Takuya https://orcid.org/0000-0001-6523-0622
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP20H05922)
MEXT | Japan Society for the Promotion of Science (JP20H00549)
MEXT | Japan Society for the Promotion of Science (JP23K10432)
MEXT | Japan Society for the Promotion of Science (JP25K22755)
MEXT | Japan Society for the Promotion of Science (JP24K02781)
Takeda Medical Research Foundation
Japan Agency for Medical Research and Development (JP19dm0207072)
Japan Agency for Medical Research and Development (JP24wm0625304)
Takeda Science Foundation
- License Information
-
More Information
Article History
Received: 17 July 2025
Revised: 12 February 2026
Accepted: 10 March 2026
First Online: 23 March 2026
Competing interests
: Takuya Takahashi is inventor of a patent application for a novel compound that specifically binds to the AMPA receptor (WO2017006931A1), including K-4. Takuya Takahashi, Tetsu Arisawa, and Waki Nakajima are inventors of a patent application (JP2025-092062, filed on June 2, 2025) based on the findings presented in this study. Takuya Takahashi and Tetsu Arisawa are founders and stockholders of AMPAMETRY, Inc., which holds the exclusive license to use K-4. The authors declare no other potential conflicts of interest.
